ASH Clinical News

The November issue is out now! Highlights include feature on alternative care models and solutions to address hematology workforce shortages, expert insight on a challenging case of relapsed extranodal NK/T-cell lymphoma, and more. See the full lineup 👉 ow.ly/uHH55103IRF

In patients with newly diagnosed #MMsm not undergoing upfront autologous HSCT, indefinite maintenance therapy with lenalidomide was not found to produce significantly longer OS when compared with fixed-duration therapy, at 68.6% vs. 69%, respectively: ow.ly/IXNp5104i3k

Preservation Disparities: Access to fertility preservation among female adolescents and young adults with #cancer varies greatly. A study found that rates of fertility preservation discussions ranged from 9% to 75% of patients.

New findings reveal that people with #SCD who received an #alloHCT have a higher baseline prevalence of low-level CH mutations associated with hematologic malignancies compared with their donors, primarily driven by mutations in DNMT3A, TET2, and TP53: ow.ly/2kJ35101SZj

In patients with R/R LBCL and follicular #lymphoma, a single infusion of CD19-directed CAR T cells produced exceptionally durable remissions and CAR T-cell persistence, with no relapses occurring beyond 5.4 years after a median follow-up of 10.1 years: ow.ly/jB5O5101qte